Cyklokapron (tranexamic acid) is a medication manufactured by Pfizer and used to stop bleeding. Cyklokapron is a type of antifibrinolytic that can also be used to treat hemophilia. Tranexamic acid, the active ingredient of Cyklokapron, is also available in generic formulations from many companies.
How Cyklokapron works
Hemophilia is a blood disorder caused by lack of a clotting factor — the proteins in the blood that cause clotting. Without clotting factors, blood clots cannot properly form after an accident or injury. Without treatment, people with severe forms of hemophilia can also have spontaneous bleeding at their joints.
Cyklokapron binds to a protein called plasminogen in the blood. Plasminogen is normally converted to an enzyme called plasmin, which degrades clots and digests or degrades clotting factors. By binding to plasminogen and preventing its conversion to plasmin, Cyklokapron increases the amount of clotting factor in the blood and encourages clot formation because newly forming clots are not being digested as quickly by plasmin.
Cyklokapron can be used alone in treating mild or moderate hemophilia or in combination with clotting factors in severe hemophilia.
Cyklokapron in clinical trials
The results of a small study (NCT00279578) of Cyklokapron in combination with clotting factor therapy in treating hemophilia A were published in the Journal of Thrombosis and Haemostasis. Eight male patients with severe hemophilia A received clotting factor therapy followed by Cyklokapron. Researchers then assessed clot formation as well as clot stability. Cyklokapron did not increase clot formation but increased the firmness and elasticity of the clots. The researchers concluded that combining Cyklokapron with clotting factor therapies can significantly improve clot stability in patients with hemophilia A.
Cyklokapron can cause side effects such as difficulty breathing during exertion, stomach pain, chills or fever, headache, and muscle cramps.